Stanton L. Gerson is an American physician and cancer researcher who currently serves as the Dean of the School of Medicine and Senior Vice President for Medical Affairs at Case Western Reserve University (CWRU).[1][2] He also holds the titles of Director of the National Center for Regenerative Medicine, the Asa and Patricia Shiverick—Jane Shiverick (Tripp) Professor of Hematological Oncology, and Distinguished University Professor at Case Western Reserve.
Stanton L. Gerson was raised in Lincoln, Massachusetts, and earned his bachelor's degree from Harvard College, where he conducted research under Boris Magasanik at MIT.[3] He received his MD from Harvard Medical School and completed a residency and hematology-oncology fellowship at the Hospital of the University of Pennsylvania.[1]
Career
Dean Gerson's research spans DNA repair mechanisms, stem cell biology, and the development of early-phase cancer clinical trials. Notably, his work on blood monitoring protocols was instrumental in FDA approval of clozapine, an antipsychotic drug. His discoveries have been licensed by companies such as Lentigen, Tracon, Novartis, Osiris.[3] He co-founded Rodeo, a privately held biopharmaceutical company focused on inhibiting 15-PGDH and bought by Amgen on March 30, 2021.[4][5][6]
He is co-editor of the international textbook Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation and the medical textbook Clinical Hematology.[1]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
